1 Most of Staphylococcus aureus and Pseudomonas aeruginosa co-infecting isolates coexist, a condition that may impact clinical outcomes in Cystic 2 Fibrosis patients. 3 4 Paul Briaud ^{a,*} (ORCID 0000-0001-7530-6803), Sylvère Bastien ^{a,*} (ORCID 0000-0002-3687-5 6 8646), Laura Camus^a (ORCID 0000-0003-1335-8901), Marie Boyadjian^b, Philippe Reix^b 7 (ORCID 0000-0002-9192-8335), Catherine Mainguy^b, François Vandenesch^{a,c} (ORCID 0000-8 0001-9412-7106), Anne Doléans-Jordheim^c (ORCID 0000-0003-4985-3955) and Karen 9 Moreau^{a,#} (ORCID 0000-0001-6297-3543). 10 11 ^a CIRI. Centre International de Recherche en Infectiologie, Université de Lvon; Inserm U1111; 12 Ecole Normale Supérieure de Lyon; Université Lyon 1 ; CNRS, UMR5308; Lyon, France 13 ^b Pediatric Pulmonology Department, Hôpital Femme-Mère-Enfant, Hospices civils de Lyon, 14 UMR5558, Lyon, France. ^c Institut des agents infectieux, Hospices Civils de Lyon, Lyon, France. 15 16 17 Running title: Coexistence of S. aureus and P. aeruginosa in CF 18 #Address correspondence to karen.moreau@univ-lyon1.fr 19 * PB and SB contributed equally to this work. Author order was determined on the basis of lab 20 position.

All rights reserved. No reuse allowed without permission.

22

23 Abstract:

24

25 Staphylococcus aureus (SA) is the major colonizer of the lung of cystic fibrosis (CF) patient 26 during childhood and adolescence. As patient aged, the prevalence of SA decreases and 27 Pseudomonas aeruginosa (PA) becomes the major pathogen infecting adult lungs. Nonetheless, 28 SA remains significant and patients harbouring both SA and PA are frequently found in worldwide cohort. Impact of coinfection remains controversial. Furthermore, co-infecting 29 30 isolates may compete or coexist. The aim of this study was to analyse if co-infection and 31 coexistence of SA and PA could lead to worse clinical outcomes. The clinical and 32 bacteriological data of 212 Lyon CF patients were collected retrospectively, and patients were 33 ranked into three groups, SA only (n=112), PA only (n=48) or SA plus PA (n=52). In addition, 34 SA and PA isolates from co-infecting patients were tested in vitro to define their interaction 35 profile. Sixty five percent (n=34) of SA/PA pairs coexist. Using univariate and multivariate 36 analysis, we confirm that SA patients have a clinical condition less severe than others, and PA 37 induce a poor outcome independently of the presence of SA. FEV1 is lower in patients infected 38 by competition strain pairs than in those infected by coexisting strain pairs compared to SA 39 mono-infection. Coexistence between SA and PA may be an important step in the natural 40 history of lung bacterial colonization within CF patients.

- 41
- 42

43 Keywords: Cystic Fibrosis, infection, *Staphylococcus aureus*, *Pseudomonas aeruginosa*,
44 clinical outcome.

46 Introduction:

47

Cystic fibrosis (CF) is the most common genetic disease among Caucasian population that affects multiple organs and causes various complications associated with patient death such as cystic fibrosis liver disease (1) (CFLD) or cystic fibrosis related diabetes (2) (CFRD) (1, 2). However, the first cause of morbidity and mortality in CF remains the progressive decrease in pulmonary function leading to an obstructive syndrome (3). This decline is generally due to the continuous inflammation provoked by polymicrobial infections (3).

54 The main clinically significant bacteria are Staphylococcus aureus (SA) and Pseudomonas 55 aeruginosa (PA). SA infection occurs early in children and affects up to 80% of patients aged 5-19 years [4]. In early childhood, SA infection is responsible for increasing inflammatory 56 57 markers [5,6] and in adolescence, patients with high SA density in throat swabs present deterioration of lung function [7]. However, despite the implication of SA in worse clinical 58 59 statue, PA, which becomes the dominant pathogen of the respiratory tract in adulthood [4] (up 60 to 60% of patients > 18 years), remains traditionally the most feared pathogen due to its strong 61 association with most severe clinical outcomes, such as a more robust inflammation, an increase 62 in the number of exacerbations and a decrease in forced expiratory volume in one second 63 (FEV1) [8-11].

Even if SA colonization decreases as patients aging, SA infection concerns more than 30% of CF adults (4). Among these cases, co-infection by PA and SA remains significant (5). However, it is difficult to determine whether this co-infection is a transitional stage between SA alone and PA alone or whether permanent co-infections with these two bacteria exist. Several *in vitro* studies deciphered the relationships between SA and PA in a context of pulmonary co-infection (6–10). According to recent studies, an evolution occurs regarding SA and PA clinical isolates interaction. PA early-colonizing isolates show a strong antagonism towards SA strains (7, 8)

especially by producing anti-staphylococcal compounds, leading to a competition state (10). However, PA isolated from chronic lung infection lack this competitiveness and SA succeeds to coexist durably with PA (6, 9, 11). In this way, we previously demonstrated that in this context of coexistence without antagonism, the two bacteria may cooperate to persist more easily in lungs (Briaud *et al.*, 2019).

76 Only few studies investigated the impact of SA-PA co-infection and clinical outcomes. In 77 addition, none of them considered the interaction state (competition vs coexistence) between 78 SA-PA. So far, available data have shown conflicting results on the link between SA-PA co-79 colonization and clinical outcomes. Ahlgren et al., did not find a significant clinical difference 80 in adult patients co-colonized with SA plus PA compared to patient colonized solely by PA 81 (12). Two studies highlighted a higher respiratory decline and rate of hospital admission for 82 patients infected by PA alone in comparison with patients co-infected by SA-PA or by SA alone 83 (5, 13). Finally, other studies reported that SA-PA co-infection is associated with a worse 84 clinical outcome (14–17).

The aim of the study was to better characterize (i) co-infected patients with demographic data (age, BMI, gender) and (ii) the interaction state (competition or coexistence) between the two bacterial species. We also examined the consequence of SA-PA co-infection and SA-PA interaction state (competition vs coexistence) on pulmonary functions (FEV1%) and clinical outcomes (e.g. number of exacerbations, number of hospitalization). By computing demographic and clinical data with pulmonary infectious status, we gain more information about the impact of SA and PA infections and interactions in CF patient's health.

- 93 Materials and Methods:
- 94
- 95 **Patients:**

96 The clinical and bacteriological data of CF patients supervised at the two CF Centers in Lyon, 97 France, (CRCM: Centre de Ressources et de Compétences de la Mucoviscidose) were collected 98 from February 2017 to August 2018. 99 The inclusion criterion was a stable microbiological status for SA and /or PA colonization, 100 defined by the following criteria: i) at least three respiratory samples collected for each patient 101 throughout the period considered (ii) at least two months between two successive samples (iii) 102 all samples collected during the study for a patient had the same status with respect to the 103 presence of SA and / or PA. The patients who did not match the criteria, or who were not co-

104 colonized by SA or PA were excluded.

105 This study was submitted to the Ethics Committee of the Hospice Civil de Lyon (HCL) and 106 registered under CNIL No 17-216. All patients were informed of the study and did not oppose 107 to the use of their data.

108

109 Clinical data gathering:

110 Clinical data were extracted from computerized medical files (Easily®). Data collected were: 111 gender, age at the time of the last sampling, CFTR genotype classified between severe and 112 moderate genotype regardless of clinical severity (5, 18), pancreatic insufficiency defined by a 113 faecal elastase < 200µg/g, CF-related diabetes (CFRD) or a carbohydrate intolerance, cirrhosis, 114 an oral or enteral supplementation and/or an undernourishment (defined as a body mass index 115 (BMI) (weight/height²) lower than 17kg/m2 in an adult and -2 standard deviations (SD) in a 116 child according to the gender and age). The pulmonary function was defined by the FEV1 117 expressed as a percentage of the predicted value (%pred). We also gathered the number of 118 hospitalizations, the length of hospital stays and the number of exacerbations during the 9 119 months preceding the last sample.

121 Microbiology:

122 The microbiological composition of each respiratory sample was determined by the Institute 123 for Infectious Agent, HCL. The interaction state (coexistence or competition) of SA-PA pairs 124 was defined by agar competition assay as previously described (Briaud et al., 2019). Briefly, 125 SA and PA isolates recovered from co-infected patient's expectorations were cultured in 10ml 126 of BHI, at 37°C, 200 rpm. From overnight cultures, SA and PA suspensions were diluted to 127 $OD_{600nm} = 0.5$. Then, 100µL of SA suspension was spread uniformly onto trypticase soy agar 128 (TSA) plates. After a drying time, 5µl of PA suspension were spotted at the centre of the plates. 129 The plates were incubated at 37°C for 24 hours. The competitive phenotype was characterized by an inhibition halo of SA growth. In absence of inhibition halo, isolates were defined in 130 131 coexistence. 132

133 Based on these microbiological analyses, the patients were categorized into four groups: (i) SA

134 alone, (ii) PA alone, (iii) or SA-PA in competition, and (iv) SA-PA in coexistence.

135

136 Statistical analysis:

137 Two different analyses were performed using the same process: (i) SA vs PA vs SA+PA, and

138 (ii) SA vs PA vs SA+PA in coexistence vs SA+PA in competition.

Factor Analysis of Mixed Data (FAMD) was used for initial data screen. Then, univariate analysis was done to determine significant differences between groups. For continuous variables (age, BMI, FEV1, number of hospitalizations, length of hospitalization and number of exacerbation), Kruskal-Wallis tests were used to identify whether a population was different from the others. Afterward, to individually test each pair of populations from significant Kruskal-Wallis tests, a Mann-Whitney Wilcoxon tests was used. Fisher's exact tests were performed to compare categorical variables (CFTR genotype, gender, Denutrition, pancreatic

146 insufficiency, CFRD, liver cirrhosis, enteral nutrition and food supply). For multiple 147 comparisons, tests were corrected by a Bonferroni method and statistical significance was set 148 with a q-value threshold at 0.05. Finally, a multinomial log-linear model (nnet package (19)) 149 was used to determine significant associations between infectious status groups and variables 150 retained by Akaike information criterion (AIC) (20). The AIC analysis was performed in order 151 to identify the smallest and fittest set of variables describing our data. An adjusted odds-ratio 152 with 95% confidence interval was reported for each final variable. All analyses were performed 153 using R v3.5.3 (21).

154

155 **Results:**

156

157 Clinical characteristics of patients

Of the 655 CF patients monitored in Lyon hospitals, we selected patients with at least three respiratory specimens with SA and / or PA during the study period. 276 patients were excluded because of the absence of the three required samples. Sixty-five patients had neither SA nor PA infection. Finally, 48 and 54 patients were excluded because of unstable SA-PA co-colonization during the period or the inability to assess their pulmonary function (age <4 years). Finally, 212 patients with CF were included in this study.

The cohort consisted of 124 adults and 88 children with a mean age of 21.70 years (range 4-69). The male-female ratio was homogeneous with approximately 51.42% (n=109) of men. About 80.66% (n=171) had a severe CFTR genotype and 41 patients had a moderate one. During this period, 39.62% (n=84) had an exacerbation and 25.94% (n=55) of the patients were hospitalized (Table S1).

169 The 212 patients were classified following their chronic bronchial colonization in 3 different 170 groups: SA alone, PA alone and SA+PA. Co-infected patients were split into 2 subclasses

171 (competition and coexistence) regarding the SA-PA interaction state determined by agar 172 competition assay (Table 1). Among the 212 patients, 52.83% (n=112) had chronic bronchial 173 colonization with SA, 22.64% (n=48) with PA and 24.53% (n=52) with SA+PA. Within the 52 174 co-infected patients, 65.38% (n=34) of SA and PA isolates presented a coexistence interaction 175 and 34.62% (n=18) presented a competition phenotype. Patients solely colonized with PA were 176 older (average of 32.02y) than co-infected patients (average of 23.38y) and themselves older 177 than patients colonized by SA (average of 16.49y) (Table 1). This is consistent with the natural 178 history of infections and international values (4).

179

180 We proceeded to a FAMD analysis to decipher the similarity and heterogeneity between patient 181 groups using both continuous and categorical variables. The two first retained axes accounted 182 for 39.47% of the total variance of the data (Fig. S1). Four variables contributed to the first axe: 183 number of exacerbations, number and days of hospitalization and FEV1. Age, BMI and not 184 having pancreatic insufficiency contributed to the second axe. The repartition of the 212 185 patients based on the two first dimensions overlaped between the 4 groups (Fig. S1). Patients 186 infected by SA were the most represented group and appeared to have clinical variable values 187 more homogeneous than other patients. On the contrary, patients co-infected in a coexistence 188 state seemed to have values with a greater heterogeneity (Fig. S1).

189

190 Impact of the co-infection on CF patient clinical outcome

In order to define whether co-infection was associated with poorer clinical outcome, we compared three groups: patients infected with SA, patients infected with PA and patients coinfected with SA-PA. Continuous variable analysis differentiated the 3 patient groups (Table 2). SA patients seemed to be younger than co-infected patients, themselves younger than PA patients (p<0.0001). SA group stood out from others by lower BMI values (PA vs SA:</p>

196 p<0.0001, SA+PA vs SA: p=0.0074), a smaller number of hospitalizations (PA vs SA: 197 p=0.0017, SA+PA vs SA: p=0.0013), a reduced length of hospitalizations (PA vs SA: 198 p=0.0011, SA+PA vs SA: p=0.0010), a lower number of exacerbations (p<0.0001) and an 199 higher FEV1 (p<0.0001). Co-infected and PA groups were not statistically different for number 200 of hospitalizations, length of hospitalizations, number of exacerbations and FEV1. Only age 201 (p=0.0012) and BMI (p=0.029) values were significantly different. For the analysis of 202 categorical variables, CFRD was only statistically significant between PA versus SA mono-203 infected group (p=0.0031) and co-infected patients versus SA (p=0.0169) (Table S2).

204 To further investigate these results and to consider potential association between variables, 205 multinomial analysis with infection type as outcome was performed using age, BMI, FEV1, 206 number of exacerbations, number of hospitalizations, length of hospitalizations and CFRD 207 (Table 3). Analyse through AIC criteria removed the three last characteristics suggesting that 208 number and length of hospitalizations and CFRD could not be associated with infection type. 209 The final model demonstrated that patients infected with PA were more likely to have a high 210 BMI [OR (95% CI): 1.2662 (1.0313, 1.5545)], a higher number of exacerbations; [OR (95% 211 CI): 2.0282 (1.2559, 3.2755)] and lower FEV1 [OR (95% CI): 0.9612 (0.9355, 0.9877)] relative 212 to patients infected with SA (Table 3). The results were similar when the co-infected group was 213 compared to SA only [OR (95% CI)]: BMI: 1.2022 (1.0015, 1.4432); exacerbations: 2.1660 214 (1.3514, 3.4078); FEV1: 0.9701 (0.9478, 0.9930)]. Comparing SA-PA group versus PA group, 215 only age criteria was significant as co-infected patients were more likely to be younger than 216 PA-mono-infected patients [OR (95% CI): 0.9477 (0.9017, 0.9961)].

217

218 Impact of the bacterial coexistence and competition within co-infected CF patients

219 The second objective of this study was to determine whether the interaction profile between SA

and PA could affect patient clinical outcome. Thus, we compared the mono-infected groups

(SA only and PA only) with two co-infected groups: SA plus PA in coexistence and SA plusPA in competition.

223 Using continuous variables, the comparison between coexistence and competition groups 224 showed no significant difference (Fig. 1). No statistical differences were also found between 225 PA mono-infected and either SA plus PA in coexistence or in competition. Compared to SA 226 groups, both SA plus PA interaction groups seemed to infect older patients (Coex. vs SA.: 227 p=0.0057; Comp. vs SA: p=0.0243) with a higher number of exacerbations (Coex. vs SA: 228 p<0.0001; Comp. vs SA: p=0.0003) and lower values of FEV1 (Coex. vs SA: p<0.0001; Comp. 229 vs SA: p=0.0001). However, it is important to notice that, for BMI, number of hospitalization 230 and length of hospitalization criteria, only coexistence group is significantly different from SA 231 groups (Fig. 1). So, coexistence group presented higher values of BMI (p=0.0449), higher 232 number of hospitalizations (p=0.0043) and longer stay of hospitalizations (p=0.0026) compared 233 to SA groups.

234 Considering categorical variables, none characteristics were statically significant between the 235 two types of interaction (Table S3). However, comparing SA group, there was higher number 236 of CFRD patients in the coexistence group (p=0.0164); such criteria was not significant when 237 SA group was compared to competition group.

238 Finally, multinomial analysis was performed using all significant characteristics from 239 univariate tests. The final predictors retained after analyses of deviance through AIC criteria 240 were BMI, supply of food, number of exacerbations and FEV1. A significant difference was 241 found between the two types of interaction in co-infected patients. The coexistence state group 242 was more likely to need food supply than the competition group [OR (95% CI): 0.2262 (0.0536, 243 0.9541)] (Table 4). As univariate results, multivariate analyses confirmed that patients co-244 infected by either a coexisting SA-PA pair, or a competition pair had higher odds of having 245 more exacerbations than those infected only by SA [OR (95% CI): 2.2896 (1.3982, 3.7494):

1.9090 (1.0956, 3.3262) respectively]. Compared to SA group, the competition state group
seemed to have lower values of FEV1 [OR (95% CI): 0.9589 (0.9300, 0.9887)] whereas the
coexistence state group were more likely to have higher BMI [OR (95% CI): 1.2047 (1.0210,
1.4213)].

250

251 Diabetes outcome and infectious status are not associated

252 Additional multivariate analyses were performed concerning CFRD patients due to statistically 253 significant difference between groups when performing univariate analyses (Table S2 and 254 Table S3). First of all, a multinomial analysis was conducted with the entire variables (including 255 the infection status) and taking CFRD as outcome. Through the analyses of deviance conducted 256 by AIC criteria, the following variables were excluded from the multinomial analysis: sex, BMI, 257 undernourishment, enteral nutrition, cirrhosis, length of hospitalisation, number of 258 exacerbations, FEV1 and type of infection. Thus, all these variables were not associated to 259 CFRD and CFRD patients were not more likely to be infected by neither SA nor PA nor 260 coinfected by SA plus PA. Five characteristics were conserved in the final model where odds 261 ratios and associated adjusted p values were reported (Table 5). CF-related diabetes patients 262 were more likely to be older [OR (95% CI): 1.1013 (1.0543, 1.1504)], to need more food supply 263 [OR (95% CI): 3.0259 (1.2297, 7.4459)] and were more hospitalized [OR (95% CI): 2.1662 264 (1.5254, 3.0763)].

265

266 **Discussion**

267

Lungs of CF patients are colonized by multiple bacteria and several studies were conducted to decipher the impact of these colonisations on the clinical outcomes. We focused our study on the two major pathogens responsible for chronic colonization: *Staphylococcus aureus* and

271 Pseudomonas aeruginosa. There is no gold standard to define chronic colonization especially 272 for SA. For PA infection, Leeds criteria (22) are sometimes used and define 'chronic' when 273 more than 50% of the preceding 12 months were PA culture positive. This definition requires 274 frequent expectoration sampling. Furthermore, these criteria may lack sensitivity and are not 275 always considered by clinicians (23). Alternatively, PA serology appears to be a sensitive 276 criterion to classify PA infection, especially in non-expectorating children but is not always 277 available (24). In order to clearly study the impact of SA and/or PA infection, we focused on 278 stabilized infections. Therefore, we considered chronic colonization when at least 3 samples 279 over a 9-month period had the same colonization pattern. These criteria are close to the 280 definition of European Consensus Criteria for PA colonisation. However, this stringent method 281 led to the exclusion of 33% of our cohort; 10% of patients were also excluded due to a change 282 in colonization status during the period studied. Finally, in our study, 52.83% of the remaining 283 patients had SA chronic colonization, 22.64% PA chronic colonization and 24.53% had chronic 284 co-colonization with both bacteria. These data are consistent with previous studies (5, 25).

285 The first point of our study was to compare the impact of chronic colonization by SA alone, PA 286 alone and SA plus PA on clinical outcome of CF patients. Indeed, being able to evaluate (or 287 even predict) the risks that a patient incurs depending on the type of bacterium and/or on 288 bacterial associations (in particular between PA and another pathogen) that colonize the lungs, 289 remains one of the major challenges in the management of patients. Thus, identifying patients 290 with harmful bacterial associations would be of clinical interest as they have increased risks of 291 worse clinical outcome. These bacterial association could become a therapeutic priority and 292 could be eradicated by targeting, for example, one of the pathogens. Conversely, we could 293 speculate that co-infection between PA and another bacterium represents a milder step in the 294 disease evolution, probably an intermediate stage between SA alone and PA alone.

295 In our study, we did not observe any differences regarding clinical status between patients co-296 infected by PA and SA and those infected by PA alone. This suggests that the SA plus PA 297 combination does not lead to over- or under morbidity compared to the presence of PA alone 298 in the lungs and that there is no addition of the effects of the two pathogens. As soon as PA 299 colonise the CF lungs, whether SA is present or not, the clinical condition of the patients appears 300 to deteriorate. This agrees with the study by Ahlgreen et al. [12] but disagree with others [5,14-301 17,22]. Indeed, studies on large size cohort with no distinction concerning age, suggested that 302 PA mono-infected group was the most severe [5,22] unlike studies on smaller cohort focus on 303 childhood concluded that co-infected group had the worst clinical outcomes [14,15,17]. In our 304 study, we did not focus on specific age class due to the limited size of the cohort. The sizes of 305 the cohorts and the age class studied could explain these dissimilarities and should be 306 considered to analyse CF clinical outcome.

307 Our results showed that SA chronic colonization conducted to a higher FEV1 (85.87± 22.39), 308 less exacerbations (0.25 ± 0.69) , a smaller number of hospitalizations (15.18% of SA patients)309 and shorter stay (8.00 ± 6.10) than SA plus PA co-infection or PA alone. This result confirms 310 previous studies (12) showing that SA infection alone is a marker of milder disease comparing 311 to PA, with less exacerbation rate and highest clinical score. Moreover, Hubert et al. (5) pointed 312 out that co-infection by methicillin-susceptible SA (MSSA) and PA was more severe (lower 313 FEV1 and higher IV antibiotic courses in one year) than mono-infection by MSSA. In the same 314 way, Cios et al. (25) found that only MSSA group was milder comparing to co-infection group. 315 Notably, association between SA alone and milder disease was not observed with MRSA. 316 Indeed, MRSA was associated with higher hospitalization rate and re-hospitalization compared 317 to co-infection. The SA methicillin resistant status seems to be, at the opposite, a severity 318 marker of SA infection in CF patients. In our cohort, only 15 MRSA cases were reported. This 319 low case number was not enough to perform analyses and conclude about impact of methicillin-

resistance status on clinical outcomes. Further studies are required to figure out why MRSA per se or as a surrogate marker of other genetic determinants- negatively impact the clinical outcome of CF patients. Moreover, other features of SA strains, such as the toxins production, could complement this analysis to more accurately describe the impact of SA in CF population.

325 CFRD is a severe complication of CF and association with bacterial infection could be used as 326 a predictive marker of severity. CFRD seemed to be overrepresented in mono-infected PA 327 (29.17%) and coinfected (25%) patients and under-represented in mono-infected SA patients 328 (8.04%). CFRD represented 16.98% of our total patients and was slightly higher to CFRD rate 329 in European population (26). Limoli et al. (16) showed that CFRD status was marginally 330 associated, with an higher odds ratio, with co-infection by both SA and PA [OR (95% CI): 1.90 331 in comparison to SA or PA mono-infection(0,99, 3,6)]. We did not confirm this result. Indeed, 332 our multivariate analysis demonstrate that CFDR was associated to the age of the patients [OR 333 (95% CI): 1.1013 (1.0543, 1.1504)]. As co-infected and PA infected patients are older than SA 334 patients, CFDR could be more represented in the two first groups. However, we cannot exclude 335 that the difference between the two studies can be explained by a lower number of patients in 336 our study.

337

The second objective of the present study was to evaluate the impact of the type of interaction between SA and PA (competition or coexistence) on clinical outcomes. Among the 52 patients co-colonized with SA and PA, 65.38% of strain pairs were in coexistent interaction and 34.61% in competition. These competitive and coexistence status were already described (6–8, 11, 27, 28). However, this is the first time that the type of interaction was evaluated in a large number of clinical isolates and we described that coexistence is the predominant interaction type in chronically co-colonized patients.

345 It has been accepted and described for a long time that PA could suppress SA growth by several 346 mechanisms (10). These data led to the theory that PA colonization causes SA elimination into 347 lungs patients. In fact, in our cohort, 24% of patients are co-colonized, which is consistent with 348 other studies (5, 16). Moreover, SA-PA pairs from co-infected patients were mostly coexisting. 349 Thus, our study shows that in 34 patients, chronical co-colonization may be due, at least in part, 350 to the inability of PA to suppress SA. It has been well described that, in CF lungs, PA strains 351 evolve and adapt from virulent early-infecting strains to less-virulent late-infecting strains (6, 352 8). Stresses induced by the pulmonary environment (oxidative and osmotic), antibiotic 353 treatments, immune system and other bacteria species, constitutes selective pressure forces for 354 adaptive mutations selection (8, 11, 17). Virulence changes could also reduce the antagonistic 355 action of the PA isolates on SA (7, 8). However, of all the factors affecting PA's evolution to 356 the pulmonary environment, the role of SA on PA evolution remains to be explored.

Nonetheless, in the present study, we did not observe a different age between patients colonized with coexisting isolates (23.24 ± 10.52) and patients colonized with competitive pairs (23.67 ± 8.98) . This suggests that there would be no link between adapted late-infecting strains and coexistence. In order to clarify this point, longitudinal studies will be necessary to evaluate the link between bacteria interaction status and isolates evolution.

362 How PA tolerance towards SA may contribute to worst clinical outcome is a point that has not 363 been explored before. Except for food supply through multinomial analyses, no significant 364 difference in clinical outcomes between patient with coexisting pairs and patients with 365 competitive pairs was observed. Nevertheless, compared to SA group, patients infected by 366 competition pair were more likely to have lower FEV1 than those infected by coexisting pair. 367 These results may suggest that competition isolates may induce a more severe disease. Several 368 quorum sensing dependent virulence factors are produced by competition PA strains such as 369 rhamnolipids and phenazines (10), that could trigger an higher inflammatory response and a

370 lower FEV1. On the contrary, coexisting PA strains lacking the production of virulence factors 371 could less damage the lung environment. The clinical outcome is therefore mainly due to the 372 genotype/phenotype of PA. However, as described previously, the PA adaptation is related to 373 many environmental factors, including the surrounding bacteria. Thus, in the coexistence 374 context, a current analysis of SA impact on PA transcriptome and growth phenotype suggests 375 that SA could favour PA persistence (Camus et al., in preparation), and then influence the 376 clinical evolution. A larger patient cohort would be necessary to evaluate the real impact of 377 coexistence state on clinical outcomes. Coexistence between SA and PA may be an important 378 step of lung bacterial colonization in CF patient, and preventing this phenomenon could 379 participate in an adapted or even personalized management of CF patients.

380

381 Ethical statement

All methods were carried out in accordance with relevant French guidelines and
regulations. This study was submitted to the Ethics Committee of the Hospices Civils de Lyon
(HCL) and registered under CNIL No 17-216.

385

386 Acknowledgments.

387 "Vaincre la mucoviscidose" and "Gregory Lemarchal" associations supported this work. P
388 Briaud was supported by French Ministry of Education and Research and L Camus was
389 supported by Fondation pour la Recherche Médicale (grant number ECO20170637499). We
390 thank Marie Verneret for technical support.

391

392 Authors' contributions:

393 PB, ADJ and KM contributed to conception and design of the study. PR, CM and FV394 contributed to design of the study. PB and LC conducted the experiments. SB conducted and

- analyzed all statistics. MB and ADJ collected the data. All authors contributed to manuscript
- 396 and approved the submitted version.
- 397 None of the authors have any conflict of interest to report.

1. Debray D, Narkewicz M, Bodewes F, Colombo C, Housset C, Jonge H de, Jonker J, Kelly D, Ling

399 **References:**

4	0	0
4	υ	υ

402		S, Poynard T, Sogni P, Trauner M, Witters P, Baumann U, Wilschanski M, Verkade H. 2017.
403		Cystic Fibrosis-related Liver Disease: Research Challenges and Future Perspectives. J Pediatr
404		Gastroenterol Nutr 65:443–448.
405	2.	Brennan AL, Beynon J. 2015. Clinical updates in cystic fibrosis-related diabetes. Semin Respir Crit
406		Care Med 36:236–250.
407	3.	Davis PB. 2006. Cystic Fibrosis Since 1938. Am J Respir Crit Care Med 173:475–482.
408	4.	Zolin, Orenti, Naehrlich, van Rens. 2019. ECFS Patient Registry Annual Data Report 2017.
409	5.	Hubert D, Réglier-Poupet H, Sermet-Gaudelus I, Ferroni A, Le Bourgeois M, Burgel P-R, Serreau
410		R, Dusser D, Poyart C, Coste J. 2013. Association between Staphylococcus aureus alone or
411		combined with Pseudomonas aeruginosa and the clinical condition of patients with cystic fibrosis.
412		J Cyst Fibros 12:497–503.
413	6.	Limoli DH, Whitfield GB, Kitao T, Ivey ML, Davis MR, Grahl N, Hogan DA, Rahme LG, Howell
414		PL, O'Toole GA, Goldberg JB. 2017. Pseudomonas aeruginosa Alginate Overproduction
415		Promotes Coexistence with Staphylococcus aureus in a Model of Cystic Fibrosis Respiratory
416		Infection. mBio 8:e00186-17.
417	7.	Baldan R, Cigana C, Testa F, Bianconi I, De Simone M, Pellin D, Di Serio C, Bragonzi A, Cirillo
418		DM. 2014. Adaptation of Pseudomonas aeruginosa in Cystic Fibrosis Airways Influences
419		Virulence of Staphylococcus aureus In Vitro and Murine Models of Co-Infection. PLoS ONE
420		9:e89614.

421	8. Michelsen CF, Christensen A-MJ, Bojer MS, Hoiby N, Ingmer H, Jelsbak L. 2014. Staphylocod	ccus
422	aureus Alters Growth Activity, Autolysis, and Antibiotic Tolerance in a Human Host-Ada	pted
423	Pseudomonas aeruginosa Lineage. J Bacteriol 196:3903-3911.	

- 424 9. Michelsen CF, Khademi SMH, Johansen HK, Ingmer H, Dorrestein PC, Jelsbak L. 2016. Evolution
 425 of metabolic divergence in Pseudomonas aeruginosa during long-term infection facilitates a proto426 cooperative interspecies interaction. ISME J 10:1323–1336.
- 427 10. Hotterbeekx A, Kumar-Singh S, Goossens H, Malhotra-Kumar S. 2017. In vivo and In vitro
 428 Interactions between Pseudomonas aeruginosa and Staphylococcus spp. Front Cell Infect
 429 Microbiol 7.
- 11. Tognon M, Köhler T, Gdaniec BG, Hao Y, Lam JS, Beaume M, Luscher A, Buckling A, van Delden
 C. 2017. Co-evolution with Staphylococcus aureus leads to lipopolysaccharide alterations in
 Pseudomonas aeruginosa. ISME J.
- 433 12. Ahlgren HG, Benedetti A, Landry JS, Bernier J, Matouk E, Radzioch D, Lands LC, Rousseau S,
 434 Nguyen D. 2015. Clinical outcomes associated with Staphylococcus aureus and Pseudomonas
 435 aeruginosa airway infections in adult cystic fibrosis patients. BMC Pulm Med 15:67.
- 436 13. Cios K, Cohen B, Quittell LM, Liu J, Larson EL. 2019. Impact of colonizing organism in the
 437 respiratory tract on the incidence, duration, and time between subsequent hospitalizations among
 438 patients with cystic fibrosis. Am J Infect Control 47:750–754.
- 439 14. Sagel SD, Gibson RL, Emerson J, McNamara S, Burns JL, Wagener JS, Ramsey BW. 2009. Impact
 440 of Pseudomonas and Staphylococcus Infection on Inflammation and Clinical Status in Young
 441 Children with Cystic Fibrosis. J Pediatr 154:183-188.e3.
- 442 15. Gangell C, Gard S, Douglas T, Park J, de Klerk N, Keil T, Brennan S, Ranganathan S, Robins443 Browne R, Sly PD, AREST CF. 2011. Inflammatory responses to individual microorganisms in
 444 the lungs of children with cystic fibrosis. Clin Infect Dis Off Publ Infect Dis Soc Am 53:425–432.

445	16. Limoli DH, Yang J, Khansaheb MK, Helfman B, Peng L, Stecenko AA, Goldberg JB. 2016.
446	Staphylococcus aureus and Pseudomonas aeruginosa co-infection is associated with cystic
447	fibrosis-related diabetes and poor clinical outcomes. Eur J Clin Microbiol Infect Dis 35:947–953.
448	17. Hudson VL, Wielinski CL, Regelmann WE. 1993. Prognostic implications of initial oropharyngeal

- bacterial flora in patients with cystic fibrosis diagnosed before the age of two years. J Pediatr
 122:854–860.
- 451 18. Welsh MJ, Smith AE. 1993. Molecular mechanisms of CFTR chloride channel dysfunction in cystic
 452 fibrosis. Cell 73:1251–1254.
- 453 19. William Venables. 2016. nnet: Feed-Forward Neural Networks and Multinomial Log-Linear454 Models.
- 455 20. Akaike H. 1998. Information Theory and an Extension of the Maximum Likelihood Principle, p.
 456 199–213. *In* Parzen, E, Tanabe, K, Kitagawa, G (eds.), Selected Papers of Hirotugu Akaike.
 457 Springer New York, New York, NY.
- 458 21. R Core Team. 2018. R: A Language and Environment for Statistical Computing. R Foundation for
 459 Statistical Computing, Vienna, Austria.
- 460 22. Lee TWR, Brownlee KG, Conway SP, Denton M, Littlewood JM. 2003. Evaluation of a new
 461 definition for chronic Pseudomonas aeruginosa infection in cystic fibrosis patients. J Cyst Fibros
 462 2:29–34.
- 463 23. Hoo ZH, Edenborough FP, Curley R, Prtak L, Dewar J, Allenby MI, Nightingale JA, Wildman MJ.
 464 2018. Understanding Pseudomonas status among adults with cystic fibrosis: a real-world
 465 comparison of the Leeds criteria against clinicians' decision. Eur J Clin Microbiol Infect Dis
 466 37:735–743.
- 467 24. Taccetti G, Denton M, Hayes K, Drevinek P, Sermet-Gaudelus I, Bilton D, Campana S, Dolce D,
 468 Ferroni A, Héry-Arnaud G, Martin-Gomez M-T, Nash E, Pereira L, Pressler T, Tümmler B. 2019.

469	A critical	review	of defi	nitions	s used to	o describe	e Pseud	lomonas	s aeruginosa	a microbiological stat	JS
											_

- in patients with cystic fibrosis for application in clinical trials. J Cyst Fibros S1569199319308677.
- 471 25. Cios K, Cohen B, Quittell LM, Liu J, Larson EL. 2019. Impact of colonizing organism in the
- 472 respiratory tract on the incidence, duration, and time between subsequent hospitalizations among
- 473 patients with cystic fibrosis. Am J Infect Control 47:750–754.
- 474 26. Kerem E, Viviani L, Zolin A, MacNeill S, Hatziagorou E, Ellemunter H, Drevinek P, Gulmans V,
- Krivec U, Olesen H. 2014. Factors associated with FEV1 decline in cystic fibrosis: analysis of the
 ECFS Patient Registry. Eur Respir J 43:125–133.
- 477 27. Cigana C, Bianconi I, Baldan R, De Simone M, Riva C, Sipione B, Rossi G, Cirillo DM, Bragonzi
- 478 A. 2017. Staphylococcus aureus impacts Pseudomonas aeruginosa chronic respiratory disease in
 479 murine models. J Infect Dis.
- 480 28. Briaud P, Camus L, Bastien S, Doléans-Jordheim A, Vandenesch F, Moreau K. 2019. Coexistence
 481 with Pseudomonas aeruginosa alters Staphylococcus aureus transcriptome, antibiotic resistance
 482 hit de line in the line in the line of th
- 482 and internalization into epithelial cells. Sci Rep 9:1–14.
- 483
- 484
- 485

486 Table 1: Clinical characteristics of CF patients according to their bacteriological status

487

	SA alone	PA alone	S	A and PA		
	(%)	(%)	competition	coexistence	merge	p_value*
Number	112/212	48/212	18/52 (34.61)	34/52 (65.38)	52/212	
Age (years)	16.49 ± 8.77	$32.02 \pm$	23.67 ± 8.98	23.24 ± 10.52	$23.38\pm$	<0.0001ª
≥18 years	45/112	42/48	14/18	23/34	37/52	
Sex, male	63/112	23/48	10/18	13/34	23/52	ns
Genotype						
Moderate	26/112	9/48	3/18	3/34	6/52	ns
Severe	86/112	39/48	15/18	31/34	46/52	
BMI (kg/m ²)	18.06 ± 2.68	20.74 ± 2.42	19.25 ± 2.56	19.71 ± 3.56	$19.55\pm$	<0.0001 ^a
Undernourishment	11/112	1/48	1/18	3/34	4/52	ns
Food supply	23/112	13/48	3/18	15/34	18/52	ns
Enteral nutrition	4/112	0/48	0/18	4/34	4/52	ns
Pancreatic	101/112	45/48	17/18	33/34	50/52	ns
CF-related diabetes	9/112	14/48	3/18	10/34	13/52	0.0007 ^b
Cirrhosis	6/112	2/48	0/18	1/34	1/52	ns
Hospitalizations during						
Number	17/112	18/48	6/18	14/34	20/52	0.0003ª
Length	8.00 ± 6.10	$17.39 \pm$	7.33 ± 6.12	29.14 ± 27.39	$22.60\pm$	0.0002 ^a
Number of	0.25 ± 0.69	1.44 ± 1.37	$1.28 \pm$	$1.35 \pm$	$1.33 \pm$	<0.0001ª
FEV1(% predicted)	$85.87 \pm$	$55.09 \pm$	59.72 ± 18.73	64.59 ± 21.79	$62.90\pm$	<0.0001ª

488 BMI: Body Mass Index

489 FEV1: Forced Expiratory Volume in one second

490 * P values from comparison between three groups: SA vs PA vs SA+PA (merge).

491 ^a P values from Kruskal-Wallis non-parametric test for comparison of the three groups (continuous

492 variables)

^b P values from Fisher's exact test for comparison of the three groups (categorical variables)

- 5
- 495 Table 2: P-values for continuous variables comparisons between SA mono-infected (SA), PA
- 496 mono-infected (PA) and co-infected groups (SA+PA). Mann-Whitney Wilcoxon non-
- 497 parametric test corrected by a Bonferroni method was used.
- 498

		SA+ PA vs	SA+PA vs
	PA vs SA	SA	РА
Age	< 0.0001	< 0.0001	0.0012
BMI	< 0.0001	0.0074	0.029
Number of hospitalizations	0.0017	0.0013	ns
Length of hospitalization	0.0011	0.0010	ns
Number of exacerbations	< 0.0001	< 0.0001	ns
FEV1	< 0.0001	< 0.0001	ns

499

Table 3: Adjusted odds ratios of cystic fibrosis patients' infection status. Multinomial regression analyses were performed to study associations between the type of infection (SA mono-infected (SA), PA mono-infected (PA) and co-infected groups (SA+PA)) and clinical outcomes. Adjusted odds ratios with 95% confidence intervals (CI) are mentioned.

	PA vs SA		SA+ PA vs	SA+ PA vs SA		SA+PA vs PA	
	OR (95 % CI)	p_value	OR (95 % CI)	p_value	OR (95 % CI)	p_value	
A ==		0 1254		0 (7(7	0.9477	0.0245	
Age	-	0.1334	-	0.0707	(0.9017, 0.9961)	0.0343	
DMI	1.2662	0.0242	1.2022	0.0404	-	0.5913	
BMI	(1.0313, 1.5545)	0.0242	(1.0015, 1.4432)	0.0481			
Number of	2.0282	0.0020	2.1460	0.0012		0.7209	
exacerbations	(1.2559, 3.2755)	0.0038	(1.3514, 3.4078)	0.0012	-	0.7298	
EEV1	0.9612	0.0042	0.9701	0.0109		0 40 47	
ΓΕΥΙ	(0.9355, 0.9877)	0.0043	(0.9478, 0.9930)	0.0108	-	0.494/	
506							

....

507

Table 4: Adjusted odds ratios of cystic fibrosis patients' infection status. Multinomial regression analyses were performed to study associations between the type of infection (SA mono-infected (SA), PA mono-infected (PA) and co-infected groups in coexistence state (Coex.), or in competition state (Comp.)) and clinical outcomes. Adjusted odds ratios with 95% confidence intervals (CI) are mentioned.

	Coex vs S.	A	Comp vs	s SA	Comp Vs C	oex
	OR (95 % CI)	p_value	OR (95 % CI)	p_value	OR (95 % CI)	p_value
BMI	1.2047 (1.0210, 1.4213)	0.0273	-	0.3199	-	0.4872
Food supply	-	0.0801	-	0.3609	0.2262 (0.0536, 0.9541)	0.0430
Number of exacerbations	2.2896 (1.3982, 3.7494)	0.0010	1.9090 (1.0956, 3.3262)	0.0228	-	0.4472
FEV1	-	0.0861	0.9589 (0.9300, 0.9887)	0.0072	-	0.1885

515

517	Table 5: Adjusted of	dds ratios of cyst	ic fibrosis-related di	iabetes (CFR)	D) patients' i	nfection
518	status. Multinomial r	egression analyse	s were performed to	study associ	ations betwee	n cystic
519	fibrosis-related diabe	tes (CFRD) and ot	her clinical outcome	s including in	fection type. A	Adjusted
520	odds ratios with 95%	confidence interv	rals (CI) are mention	ed.		
521					_	
522			OR (95 % CI)	p_value		
523		A	1.1013	<0.0001	-	
524		Age	(1.0543, 1.1504)	<0.0001		
525		Genotype	-	0.1022		
526			3.0259			
527		Food supply	(1.2297, 7.4459)	0.0160		
528		Pancreatic		0.0100		
529		insufficiency	-	0.8192		
530		Number of	2.1662	<0.0001		
531		hospitalizations	(1.5254, 3.0763)	<0.0001		
532					-	
533						
534						
535						
536						
537						
538						



539

540 Fig 1: Comparison between SA mono-infected (SA), PA mono-infected (PA) and co-infected

541 groups in competition (Comp) or in coexistence (Coex). Mann-Whitney Wilcoxon non-

542 parametric test corrected by a Bonferroni method was used

544 Supplementary data

- 545
- 546
- 547



548 Fig. S1: Individual factor map from FAMD based on 212 patients using the two first principal 549 components. Patients are colored according to their infection type, SA mono-infected (red), PA 550 mono-infected (yellow), SA+PAcoinfection in a competition state (blue), SA+PA coinfection 551 in a coexistence state (cyan). Associated eigenvalue plot is shown at the top right.

553 Table S1: Patients characteristics at the time of the study

	Numbers of	Mean \pm SD or
Baseline characteristics	patients	Percentage
Age (years)	212	21.70 ± 12.09
≥18 years	124/212	58.49%
Sex, male	109/212	51.42%
Genotype		
Moderate	41/212	19.34%
Severe	171/212	80.66%
BMI (kg/m ²)	212	19.03 ± 2.97
Undernourishment	16/212	7.55%
Food supply	54/212	25.47%
Enteral nutrition	8/212	3.77%
Pancreatic sufficiency	16/212	7.55%
CF-related diabetes	36/212	16.98%
Cirrhosis	9/212	4.25%
Hospitalizations during		
study period	55/212	25.94%
Number		1.96 ± 1.17
Length (days)		16.38 ± 18.28
Exacerbations*	84	0.78 ± 1.24
FEV1 (% predicted)	212	73.27 ± 25.12

- 554 BMI: body mass index
- 555 FEV1: forced expiratory volume in one second
- 556 * Corresponding to total number of exacerbations

- 557 Table S2: P-values for categorical variables comparisons between S. aureus mono-infected
- 558 (SA), *P. aeruginosa* mono-infected (PA) and co-infected groups (SA+PA). Fisher's exact test
- 559 corrected with a Bonferroni method was used.
- 560
- 561

	PA vs SA	SA+ PA vs SA	SA+PA vs PA
Sex	-	-	-
Genotype	-	-	-
Undernourishment	-	-	-
Food supply	-	-	-
Enteral nutrition	-	-	-
Pancreatic			
sufficiency	-	-	-
CF-related	0.0021	0.01/0	
diabetes	0.0031	0.0169	ns
Liver cirrhosis	-	-	-

564

562

- 565 Table S3: P-values for categorical variables comparisons between S. aureus mono-infected
- 566 (SA), *P. aeruginosa* mono-infected (PA), co-infected in a coexistence (Coex) state and co-
- 567 infected in a competition (Comp) state group.
- 568

					Comp.
	Coex vs	Comp vs	Coex	Comp	Ĩ
	S۸	S۸	νς ΡΛ	νεΡΛ	VS
	SA	SA	VSIA	V31 A	Coex
Sex	-	-	-	-	-
Genotype	-	-	-	-	-
Undernourishment	-	-	-	-	-
Food supply	ns	ns	ns	ns	ns
Enteral nutrition	-	-	-	-	-
Pancreatic					
insufficiency	-	-	-	-	-
CF-related	0.0164				
diabetes	0.0164	ns	ns	ns	ns
Liver cirrhosis	-	-	-	-	-

569